PMID: 8592688Nov 1, 1995Paper

Ocular availability of gentamicin in small animals after topical administration of a conventional eye drop solution and a novel long acting bioadhesive ophthalmic drug insert

Pharmaceutical Research
F GurtlerR Gurny

Abstract

Gentamicin eye drop solutions have a short precorneal residence time. The present study investigates the effect of gentamicin using a new long acting delivery Bioadhesive Ophthalmic Insert (BODI) in healthy dogs and rabbits and compares the results with a conventional regimen using an eye drop solution. In vivo assays were performed on animals after deposition of one BODI and instillations of an eye drop solution. Tear samples were collected over 72 hours and 60 minutes, in the case of inserts and eye drop solution respectively. The gentamicin concentration profiles in tear fluid (determined by a fluorescent polarization immunoassay technique) was individually analyzed, in each animal, in relation with the minimum inhibitory concentration observed in vitro against some bacteria. A non classical pharmacokinetic approach was used for the analysis of the topically applied drug substance, involving two parameters: the efficacy area under the curve (AUCeff) and the efficacy time (teff). In the case of the eye drop solution, the AUCeff were higher in dogs (2.80 10(3) - 3.64 10(3) [micrograms ml-1 h]) than in rabbits (0.64 x 10(3) - 0.95 x 10(3) [micrograms ml-1 h]); the teff had a similar behavior: 6-15 [h] in dogs and 2-6 [h] in rab...Continue Reading

Citations

Sep 7, 2007·Journal of Veterinary Pharmacology and Therapeutics·F GasthuysJ P Remon
Dec 18, 2013·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·K BellF H Grus
Jul 22, 1998·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·V BaeyensR Gurny
Apr 5, 2001·Clinical Pharmacokinetics·J Woodley
Mar 31, 2009·Expert Opinion on Drug Delivery·Thirumurthy Velpandian
Jun 12, 2002·Drug Development and Industrial Pharmacy·Indu Pal Kaur, R Smitha
Aug 1, 1998·Journal of Controlled Release : Official Journal of the Controlled Release Society·V BaeyensR Gurny
Nov 3, 2020·Bioconjugate Chemistry·Arijit Basu, Abraham J Domb
Jun 14, 2020·Pharmaceutical Nanotechnology·Classius Ferreira da SilvaPatrícia Severino

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Related Papers

Expert Opinion on Drug Delivery
Lisa C du ToitTrevor Carmichael
Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie
S F BernatchezR Gurny
Optometry and Vision Science : Official Publication of the American Academy of Optometry
Jerry R PaughDavid L Meadows
© 2021 Meta ULC. All rights reserved